English
Insider transactions
EDGARAdicet Bio, Inc.
Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.
A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.
Window: transactions dated on or after 2025-11-21.
- Open-market purchases (code P)
- 3 transactions, 223,596 shares
- Sum of shares × price per share: 1,603,934.13
- Open-market sales (code S)
- 4 transactions, 104,658 shares
- Sum of shares × price per share: 674,847.06
Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.
Showing 1–27 of 27
| Date | Reporting owner | Code | Acquired or disposed | Shares | Price per share, as filed | Value (derived) | Shares owned after | Direct or indirect | Rule 10b5-1 box | Notes | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 Filed 2026-08-07 | Klickstein Lloyd Director · Officer: Chief Medical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 18,300 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 18,300 | Direct (D) | No | F1
| Open filing 0001776004-26-000003 Read from the filing’s XML Dispute this row |
| 2026-06-21 Filed 2026-06-23 | DUBIN STEVE Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 4,200 | 0 | — | 4,200 | Direct (D) | No | F1
| Open filing 0001265123-26-000001 Read from the filing’s XML Dispute this row |
| 2026-06-21 Filed 2026-06-23 | Peng Katie Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 4,200 | 0 | — | 4,200 | Direct (D) | No | F1
| Open filing 0001983850-26-000001 Read from the filing’s XML Dispute this row |
| 2026-06-21 Filed 2026-06-23 | Sinclair Andrew Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 4,200 | 0 | — | 4,200 | Direct (D) | No | F1
| Open filing 0001762451-26-000002 Read from the filing’s XML Dispute this row |
| 2026-06-21 Filed 2026-06-23 | Grissinger Michael Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 4,200 | 0 | — | 4,200 | Direct (D) | No | F1
| Open filing 0001757601-26-000002 Read from the filing’s XML Dispute this row |
| 2026-06-21 Filed 2026-06-23 | Klickstein Lloyd Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 4,200 | 0 | — | 4,200 | Direct (D) | No | F1
| Open filing 0001776004-26-000001 Read from the filing’s XML Dispute this row |
| 2026-06-21 Filed 2026-06-23 | Chodakewitz Jeffrey Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 4,200 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 4,200 | Direct (D) | No | F1
| Open filing 0001610876-26-000002 Read from the filing’s XML Dispute this row |
| 2026-06-19 Filed 2026-06-23 | Schor Chen Director · Officer: President CEO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 55,000 | 0 | — | 55,000 | Direct (D) | No | F1
| Open filing 0001340875-26-000007 Read from the filing’s XML Dispute this row |
| 2026-06-19 Filed 2026-06-23 | Aftab Blake Officer: Chief Scientific Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 55,000 | 0 | — | 55,000 | Direct (D) | No | F1
| Open filing 0001886986-26-000004 Read from the filing’s XML Dispute this row |
| 2026-04-27 Filed 2026-04-29 | RA CAPITAL MANAGEMENT, L.P. 10% ownerRA Capital Healthcare Fund LP 10% ownerKolchinsky Peter 10% ownerShah Rajeev M. 10% owner | JOther acquisition or disposition (describe transaction) | Disposed (D) | 250,000 | — | — | 932,624 | Indirect (I) See footnotes | No | F1, F2, F3
| Open filing 0001231919-26-000425 Read from the filing’s XML Dispute this row |
| 2026-04-27 Filed 2026-04-29 | RA CAPITAL MANAGEMENT, L.P. 10% ownerRA Capital Healthcare Fund LP 10% ownerKolchinsky Peter 10% ownerShah Rajeev M. 10% owner | JOther acquisition or disposition (describe transaction) | Acquired (A) | 250,000 | — | — | 1,402,833 | Indirect (I) See footnotes | No | F1, F4, F2, F3
| Open filing 0001231919-26-000425 Read from the filing’s XML Dispute this row |
| 2026-04-08 Filed 2026-04-09 | ORBIMED ADVISORS LLC 10% ownerOrbiMed Capital GP V LLC 10% ownerOrbiMed Capital GP VI LLC 10% ownerOrbiMed Genesis GP LLC 10% ownerOrbiMed Advisors Israel II Ltd 10% ownerOrbiMed Israel GP II, L.P. 10% ownerOrbiMed Israel GP Ltd. 10% ownerOrbiMed Israel BioFund GP Limited Partnership 10% owner | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 32,523 | 6.29 | 204,569.67Derived: shares × price per share. Exact value 204569.67. | 0 | Indirect (I) See footnotes | No | F1, F6
| Open filing 0000947871-26-000421 Read from the filing’s XML Dispute this row |
| 2026-04-08 Filed 2026-04-09 | ORBIMED ADVISORS LLC 10% ownerOrbiMed Capital GP V LLC 10% ownerOrbiMed Capital GP VI LLC 10% ownerOrbiMed Genesis GP LLC 10% ownerOrbiMed Advisors Israel II Ltd 10% ownerOrbiMed Israel GP II, L.P. 10% ownerOrbiMed Israel GP Ltd. 10% ownerOrbiMed Israel BioFund GP Limited Partnership 10% owner | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 40,416 | 6.52 | 263,512.32Derived: shares × price per share. Exact value 263512.32. | 0 | Indirect (I) See footnotes | No | F2, F6
| Open filing 0000947871-26-000421 Read from the filing’s XML Dispute this row |
| 2026-04-07 Filed 2026-04-09 | ORBIMED ADVISORS LLC 10% ownerOrbiMed Capital GP V LLC 10% ownerOrbiMed Capital GP VI LLC 10% ownerOrbiMed Genesis GP LLC 10% ownerOrbiMed Advisors Israel II Ltd 10% ownerOrbiMed Israel GP II, L.P. 10% ownerOrbiMed Israel GP Ltd. 10% ownerOrbiMed Israel BioFund GP Limited Partnership 10% owner | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 29,319 | 6.53 | 191,453.07Derived: shares × price per share. Exact value 191453.07. | 34,923 | Indirect (I) See footnotes | No | F1, F6
| Open filing 0000947871-26-000421 Read from the filing’s XML Dispute this row |
| 2026-04-07 Filed 2026-04-09 | ORBIMED ADVISORS LLC 10% ownerOrbiMed Capital GP V LLC 10% ownerOrbiMed Capital GP VI LLC 10% ownerOrbiMed Genesis GP LLC 10% ownerOrbiMed Advisors Israel II Ltd 10% ownerOrbiMed Israel GP II, L.P. 10% ownerOrbiMed Israel GP Ltd. 10% ownerOrbiMed Israel BioFund GP Limited Partnership 10% owner | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 2,400 | 6.38 | 15,312Derived: shares × price per share. Exact value 15312.00. | 32,523 | Indirect (I) See footnotes | No | F1, F6
| Open filing 0000947871-26-000421 Read from the filing’s XML Dispute this row |
| 2026-03-25 Filed 2026-03-27 | Aftab Blake Officer: Chief Scientific Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 72,555 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 72,555 | Direct (D) | No | F1
| Open filing 0001886986-26-000002 Read from the filing’s XML Dispute this row |
| 2026-03-25 Filed 2026-03-27 | Healey Don Officer: Chief Technology Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 43,361 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 43,361 | Direct (D) | No | F1
| Open filing 0001643067-26-000002 Read from the filing’s XML Dispute this row |
| 2026-03-25 Filed 2026-03-27 | Maltzman Julia D. Officer: Chief Medical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 72,555 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 72,555 | Direct (D) | No | F1
| Open filing 0002052749-26-000003 Read from the filing’s XML Dispute this row |
| 2026-03-25 Filed 2026-03-27 | Schor Chen Director · Officer: President CEO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 468,555 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 468,555 | Direct (D) | No | F1
| Open filing 0001340875-26-000003 Read from the filing’s XML Dispute this row |
| 2026-03-25 Filed 2026-03-27 | Harvey Brian Nicholas Officer: Chief Financial Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 43,361 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 43,361 | Direct (D) | No | F1
| Open filing 0001519432-26-000002 Read from the filing’s XML Dispute this row |
| 2026-02-20 Filed 2026-04-13 | RA CAPITAL MANAGEMENT, L.P. 10% ownerRA Capital Healthcare Fund LP 10% ownerKolchinsky Peter 10% ownerShah Rajeev M. 10% owner | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 74,751 | 7.27 | 543,439.77Derived: shares × price per share. Exact value 543439.77. | 1,182,624 | Indirect (I) See footnotes | No | F5, F2, F3
| Open filing 0001231919-26-000337 Read from the filing’s XML Dispute this row |
| 2026-02-19 Filed 2026-04-13 | RA CAPITAL MANAGEMENT, L.P. 10% ownerRA Capital Healthcare Fund LP 10% ownerKolchinsky Peter 10% ownerShah Rajeev M. 10% owner | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 74,268 | 7.21 | 535,472.28Derived: shares × price per share. Exact value 535472.28. | 1,107,873 | Indirect (I) See footnotes | No | F4, F2, F3
| Open filing 0001231919-26-000337 Read from the filing’s XML Dispute this row |
| 2026-02-18 Filed 2026-04-13 | RA CAPITAL MANAGEMENT, L.P. 10% ownerRA Capital Healthcare Fund LP 10% ownerKolchinsky Peter 10% ownerShah Rajeev M. 10% owner | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 74,577 | 7.04 | 525,022.08Derived: shares × price per share. Exact value 525022.08. | 1,033,605 | Indirect (I) See footnotes | No | F1, F2, F3
| Open filing 0001231919-26-000337 Read from the filing’s XML Dispute this row |
| 2026-01-24 Filed 2026-01-27 | Harvey Brian Nicholas Officer: Chief Financial Officer | FPayment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Disposed (D) | 546 | 8.44 | 4,608.24Derived: shares × price per share. Exact value 4608.24. | 5,145 | Direct (D) | No | F1, F2
| Open filing 0001193125-26-024746 Read from the filing’s XML Dispute this row |
| 2026-01-24 Filed 2026-01-27 | Schor Chen Director · Officer: President CEO | FPayment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Disposed (D) | 1,755 | 8.44 | 14,812.2Derived: shares × price per share. Exact value 14812.20. | 6,820 | Direct (D) | No | F1, F2
| Open filing 0001193125-26-024749 Read from the filing’s XML Dispute this row |
| 2026-01-24 Filed 2026-01-27 | Healey Don Officer: Chief Technology Officer | FPayment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Disposed (D) | 535 | 8.44 | 4,515.4Derived: shares × price per share. Exact value 4515.40. | 3,452 | Direct (D) | No | F1, F2
| Open filing 0001193125-26-024753 Read from the filing’s XML Dispute this row |
| 2026-01-24 Filed 2026-01-27 | Aftab Blake Officer: Chief Scientific Officer | FPayment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Disposed (D) | 535 | 8.44 | 4,515.4Derived: shares × price per share. Exact value 4515.40. | 2,981 | Direct (D) | No | F1, F2
| Open filing 0001193125-26-024755 Read from the filing’s XML Dispute this row |
Institutional holders (Form 13F)
Quarter ending 2026-09-30: 8,925 filings read, the latest filed 2026-11-20. Prior quarter ending 2026-06-30: 9,176 filings read.
Showing 1–50 of 61
| Manager | Shares or principal | Value as filed | Change from the prior quarter | Source |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 932,624 SH | 6,658,935 dollars | Unchanged Prior quarter: 932,624 | Open filing 0001104659-26-128411 Filed 2026-11-16 Dispute this row |
| ORBIMED ADVISORS LLC | 844,787 SH | 6,031,779 dollars | Unchanged Prior quarter: 844,787 | Open filing 0001172661-26-005349 Filed 2026-11-16 Dispute this row |
| FRANKLIN TEMPLETON INC Partly reported under another manager | 724,138 SH | 2,244,828 dollars | Higher by 97,567 Prior quarter: 626,571 | Open filing 0000038777-26-000291 Filed 2026-11-12 Dispute this row |
| VANGUARD CAPITAL MANAGEMENT LLC | 366,216 SH | 2,614,782 dollars | Higher by 22,988 Prior quarter: 343,228 | Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row |
| CITADEL ADVISORS LLC Partly reported under another manager | 280,372 SH | 2,001,856 dollars | Lower by 152,366 Prior quarter: 432,738 | Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row |
| RENAISSANCE TECHNOLOGIES LLC Partly reported under another manager | 214,841 SH | 1,533,965 dollars | Lower by 51,104 Prior quarter: 265,945 | Open filing 0001037389-26-000062 Filed 2026-11-12 Dispute this row |
| Alyeska Investment Group, L.P. | 203,799 SH | 1,455,125 dollars | Unchanged Prior quarter: 203,799 | Open filing 0001172661-26-005329 Filed 2026-11-16 Dispute this row |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 193,125 SH | 1,378,913 dollars | Lower by 81,250 Prior quarter: 274,375 | Open filing 0001172661-26-005200 Filed 2026-11-16 Dispute this row |
| Schonfeld Strategic Advisors LLC | 188,948 SH | 1,349,087 dollars | Lower by 6,566 Prior quarter: 195,514 | Open filing 0001665241-26-000003 Filed 2026-11-16 Dispute this row |
| Stonepine Capital Management, LLC | 188,201 SH | 1,343,755 dollars | Lower by 57,317 Prior quarter: 245,518 | Open filing 0001440771-26-000027 Filed 2026-11-13 Dispute this row |
| Carlyle Group Inc. Partly reported under another manager | 184,295 SH | 1,315,865 dollars | Unchanged Prior quarter: 184,295 | Open filing 0000898432-26-000769 Filed 2026-11-06 Dispute this row |
| ACADIAN ASSET MANAGEMENT LLC Partly reported under another manager | 170,832 SH | 1,217 dollars | Higher by 46,000 Prior quarter: 124,832 | Open filing 0001140361-26-042753 Filed 2026-11-09 Dispute this row |
| UBS Group AG Partly reported under another manager | 118,197 SH | 843,927 dollars | Higher by 88,380 Prior quarter: 29,817 | Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row |
| DAFNA Capital Management LLC | 93,812 SH | 669,818 dollars | Unchanged Prior quarter: 93,812 | Open filing 0001389933-26-000010 Filed 2026-11-16 Dispute this row |
| Trexquant Investment LP Partly reported under another manager | 89,813 SH | 641,265 dollars | Higher by 11,811 Prior quarter: 78,002 | Open filing 0001633445-26-000008 Filed 2026-11-16 Dispute this row |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 85,959 SH | 613,747 dollars | Unchanged Prior quarter: 85,959 | Open filing 0001107261-26-000007 Filed 2026-11-16 Dispute this row |
| GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager | 84,847 SH | 606,163 dollars | Lower by 10,787 Prior quarter: 95,634 | Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row |
| TWO SIGMA INVESTMENTS, LP | 72,915 SH | 520,613 dollars | Lower by 23,924 Prior quarter: 96,839 | Open filing 0000899140-26-001341 Filed 2026-11-16 Dispute this row |
| MARSHALL WACE, LLP Partly reported under another manager | 69,235 SH | 494,338 dollars | Lower by 10,253 Prior quarter: 79,488 | Open filing 0001318757-26-000012 Filed 2026-11-13 Dispute this row |
| Rangeley Capital, LLC | 64,000 SH | 456,960 dollars | Higher by 13,108 Prior quarter: 50,892 | Open filing 0001892688-26-000185 Filed 2026-11-16 Dispute this row |
| Burkehill Global Management, LP | 62,500 SH | 446,250 dollars | Unchanged Prior quarter: 62,500 | Open filing 0001013594-26-001202 Filed 2026-11-16 Dispute this row |
| BlackRock, Inc. Partly reported under another manager | 61,024 SH | 435,711 dollars | Lower by 1,102 Prior quarter: 62,126 | Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row |
| REGENERON PHARMACEUTICALS, INC. | 60,511 SH | 432,049 dollars | Unchanged Prior quarter: 60,511 | Open filing 0001104659-26-123321 Filed 2026-11-05 Dispute this row |
| VANGUARD FIDUCIARY TRUST CO | 50,670 SH | 361,784 dollars | Unchanged Prior quarter: 50,670 | Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row |
| Verdad Advisers, LP | 47,546 SH | 339,478 dollars | Higher by 22,346 Prior quarter: 25,200 | Open filing 0001420506-26-002833 Filed 2026-11-16 Dispute this row |
| DIMENSIONAL FUND ADVISORS LP Partly reported under another manager | 38,138 SH | 272,305 dollars | Higher by 6,535 Prior quarter: 31,603 | Open filing 0000354204-26-001096 Filed 2026-11-04 Dispute this row |
| STATE STREET CORP Partly reported under another manager | 36,222 SH | 258,625 dollars | Unchanged Prior quarter: 36,222 | Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row |
| RBF Capital, LLC | 36,082 SH | 257,625 dollars | Lower by 2,500 Prior quarter: 38,582 | Open filing 0001062993-26-005971 Filed 2026-11-13 Dispute this row |
| CITADEL ADVISORS LLC Option: Put Partly reported under another manager | 35,400 SH | 252,756 dollars | Higher by 12,600 Prior quarter: 22,800 | Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row |
| JANE STREET GROUP, LLC Partly reported under another manager | 25,980 SH | 185,498 dollars | Lower by 44,581 Prior quarter: 70,561 | Open filing 0001595888-26-000162 Filed 2026-11-12 Dispute this row |
| PRELUDE CAPITAL MANAGEMENT, LLC | 24,862 SH | 177,515 dollars | Higher by 6,312 Prior quarter: 18,550 | Open filing 0000945621-26-001415 Filed 2026-11-16 Dispute this row |
| Connor, Clark Lunn Investment Management Ltd. | 23,308 SH | 166,419 dollars | Not in the prior quarter’s filings read | Open filing 0001596800-26-000018 Filed 2026-11-10 Dispute this row |
| JOHNSON JOHNSON Partly reported under another manager | 22,779 SH | 162,642 dollars | Unchanged Prior quarter: 22,779 | Open filing 0000904454-26-000541 Filed 2026-10-26 Dispute this row |
| NORTHERN TRUST CORP Partly reported under another manager | 18,436 SH | 131,633 dollars | Unchanged Prior quarter: 18,436 | Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row |
| CITADEL ADVISORS LLC Option: Call Partly reported under another manager | 14,000 SH | 99,960 dollars | Higher by 3,290 Prior quarter: 10,710 | Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row |
| Engineers Gate Manager LP | 12,950 SH | 92,463 dollars | Not in the prior quarter’s filings read | Open filing 0001620220-26-000010 Filed 2026-11-16 Dispute this row |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP Partly reported under another manager | 12,942 SH | 92,406 dollars | Lower by 7,708 Prior quarter: 20,650 | Open filing 0001446194-26-000009 Filed 2026-11-16 Dispute this row |
| Vontobel Holding Ltd. Partly reported under another manager | 12,775 SH | 91,214 dollars | Lower by 1,001 Prior quarter: 13,776 | Open filing 0001588340-26-000004 Filed 2026-10-16 Dispute this row |
| OCCUDO QUANTITATIVE STRATEGIES LP | 12,310 SH | 87,893 dollars | Lower by 4,326 Prior quarter: 16,636 | Open filing 0001420506-26-002797 Filed 2026-11-16 Dispute this row |
| MORGAN STANLEY Partly reported under another manager | 10,836 SH | 77,370 dollars | Higher by 8,545 Prior quarter: 2,291 | Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row |
| JANE STREET GROUP, LLC Option: Call Partly reported under another manager | 10,600 SH | 75,684 dollars | Not in the prior quarter’s filings read | Open filing 0001595888-26-000162 Filed 2026-11-12 Dispute this row |
| Arax Advisory Partners Partly reported under another manager | 6,001 SH | 42,845 dollars | Higher by 1 Prior quarter: 6,000 | Open filing 0001586767-26-000009 Filed 2026-11-12 Dispute this row |
| CITIGROUP INC Partly reported under another manager | 4,721 SH | 33,708 dollars | Not in the prior quarter’s filings read | Open filing 0000831001-26-000052 Filed 2026-11-04 Dispute this row |
| BNP PARIBAS FINANCIAL MARKETS Partly reported under another manager | 3,573 SH | 25,511 dollars | Higher by 3,523 Prior quarter: 50 | Open filing 0001166588-26-000012 Filed 2026-11-12 Dispute this row |
| SIMPLEX TRADING, LLC Option: Call | 2,800 SH | 19,992 dollars | Higher by 1,100 Prior quarter: 1,700 | Open filing 0001488542-26-000013 Filed 2026-11-04 Dispute this row |
| Vanguard Global Advisers, LLC | 2,070 SH | 14,780 dollars | Lower by 3,151 Prior quarter: 5,221 | Open filing 0001811242-26-000017 Filed 2026-11-13 Dispute this row |
| ROYAL BANK OF CANADA Partly reported under another manager | 1,988 SH | 14,000 dollars | Higher by 287 Prior quarter: 1,701 | Open filing 0001140361-26-044123 Filed 2026-11-16 Dispute this row |
| GROUP ONE TRADING LLC Option: Call | 1,100 SH | 7,854 dollars | Not in the prior quarter’s filings read | Open filing 0000932540-26-000017 Filed 2026-11-10 Dispute this row |
| Tower Research Capital LLC (TRC) Partly reported under another manager | 1,038 SH | 7,412 dollars | Higher by 761 Prior quarter: 277 | Open filing 0001533421-26-000010 Filed 2026-11-16 Dispute this row |
| SIMPLEX TRADING, LLC | 934 SH | 6,668 dollars | Lower by 3,880 Prior quarter: 4,814 | Open filing 0001488542-26-000013 Filed 2026-11-04 Dispute this row |
Managers in the prior quarter with no filing read for the latest
They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.
- NEXTBio Capital Management LP 157,827 SH
- Quadrature Capital Ltd 36,193 SH
- XTX Topco Ltd 24,284 SH
- SUSQUEHANNA INTERNATIONAL GROUP, LLP 19,600 SH
- Squarepoint Ops LLC 15,254 SH
- AXQ CAPITAL, LP 10,991 SH
- Jump Financial, LLC 10,942 SH
- FMR LLC 6 SH
- Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
- Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
- A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
- A change is the difference between two quarter-end snapshots, not a trade.
- A position reported under another manager may also appear in that manager’s filing; rows are not added together.
- Holdings the securities list cannot place with this company, or places ambiguously, are not shown.
Trades by members of Congress
Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.
No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.
5% holders (Schedule 13D and 13G)
Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.
| Holder | Percent of class | Shares held | Event date | Form | Source |
|---|---|---|---|---|---|
| Zedek Daniel Clayton Common Stock, $0.0001 par vaue | 5.4 | 502,309.00 | 10/19/2026 Filed 2026-10-23 | SCHEDULE 13G | Open filing 0002161951-26-000001 Dispute this row |
| Zedek Lauren Marie Common Stock, $0.0001 par vaue | 5.4 | 502,309.00 | 10/19/2026 Filed 2026-10-23 | SCHEDULE 13G | Open filing 0002161951-26-000001 Dispute this row |
| Franklin Templeton, Inc. Common Stock, par value $0.0001 per share | 7.7 | 724,138.00 | 09/30/2026 Filed 2026-10-28 | SCHEDULE 13G/AAmendment 1 | Open filing 0000038777-26-000272 Dispute this row |
| Charles B. Johnson Common Stock, par value $0.0001 per share | 0 | 0.00 | 09/30/2026 Filed 2026-10-28 | SCHEDULE 13G/AAmendment 1 | Open filing 0000038777-26-000272 Dispute this row |
| Rupert H. Johnson, Jr. Common Stock, par value $0.0001 per share | 0 | 0.00 | 09/30/2026 Filed 2026-10-28 | SCHEDULE 13G/AAmendment 1 | Open filing 0000038777-26-000272 Dispute this row |
| Franklin Advisers, Inc. Common Stock, par value $0.0001 per share | 7.7 | 724,138.00 | 09/30/2026 Filed 2026-10-28 | SCHEDULE 13G/AAmendment 1 | Open filing 0000038777-26-000272 Dispute this row |
| RA Capital Management, L.P. Common Stock, par value $0.0001 per share | 9.9 | 935,486.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 4 | Open filing 0001231919-26-000916 Dispute this row |
| Peter Kolchinsky Common Stock, par value $0.0001 per share | 9.9 | 935,486.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 4 | Open filing 0001231919-26-000916 Dispute this row |
| Rajeev Shah Common Stock, par value $0.0001 per share | 9.9 | 935,486.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 4 | Open filing 0001231919-26-000916 Dispute this row |
| RA Capital Healthcare Fund, L.P. Common Stock, par value $0.0001 per share | 9.9 | 935,486.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 4 | Open filing 0001231919-26-000916 Dispute this row |
| ORBIMED ADVISORS LLC Common Stock, par value $0.0001 | 8.8 | 844,787.00 | 04/08/2026 Filed 2026-04-10 | SCHEDULE 13D/AAmendment 9 | Open filing 0000947871-26-000427 Dispute this row |
| ORBIMED CAPITAL GP VI LLC Common Stock, par value $0.0001 | 2.9 | 280,640.00 | 04/08/2026 Filed 2026-04-10 | SCHEDULE 13D/AAmendment 9 | Open filing 0000947871-26-000427 Dispute this row |
| ORBIMED CAPITAL GP V LLC Common Stock, par value $0.0001 | 5.9 | 564,147.00 | 04/08/2026 Filed 2026-04-10 | SCHEDULE 13D/AAmendment 9 | Open filing 0000947871-26-000427 Dispute this row |
| OrbiMed Genesis GP LLC Common Stock, par value $0.0001 | 0 | 0.00 | 04/08/2026 Filed 2026-04-10 | SCHEDULE 13D/AAmendment 9 | Open filing 0000947871-26-000427 Dispute this row |
| ORBIMED ADVISORS ISRAEL II LTD Common Stock, par value $0.0001 | 0 | 0.00 | 04/08/2026 Filed 2026-04-10 | SCHEDULE 13D/AAmendment 9 | Open filing 0000947871-26-000427 Dispute this row |
| ORBIMED ISRAEL GP II, L.P. Common Stock, par value $0.0001 | 0 | 0.00 | 04/08/2026 Filed 2026-04-10 | SCHEDULE 13D/AAmendment 9 | Open filing 0000947871-26-000427 Dispute this row |
| ORBIMED ISRAEL GP LTD. Common Stock, par value $0.0001 | 0 | 0.00 | 04/08/2026 Filed 2026-04-10 | SCHEDULE 13D/AAmendment 9 | Open filing 0000947871-26-000427 Dispute this row |
| ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIP Common Stock, par value $0.0001 | 0 | 0.00 | 04/08/2026 Filed 2026-04-10 | SCHEDULE 13D/AAmendment 9 | Open filing 0000947871-26-000427 Dispute this row |
| Woodline Partners LP Common Stock, par value $0.0001 per share | 3.3 | 313,124.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 1 | Open filing 0000919574-26-003239 Dispute this row |
| RA Capital Management, L.P. Common Stock, par value $0.0001 per share | 12.3 | 1,182,624.00 | 02/17/2026 Filed 2026-04-13 | SCHEDULE 13G/AAmendment 3 | Open filing 0001346824-26-000105 Dispute this row |
| Peter Kolchinsky Common Stock, par value $0.0001 per share | 12.3 | 1,182,624.00 | 02/17/2026 Filed 2026-04-13 | SCHEDULE 13G/AAmendment 3 | Open filing 0001346824-26-000105 Dispute this row |
| Rajeev Shah Common Stock, par value $0.0001 per share | 12.3 | 1,182,624.00 | 02/17/2026 Filed 2026-04-13 | SCHEDULE 13G/AAmendment 3 | Open filing 0001346824-26-000105 Dispute this row |
| RA Capital Healthcare Fund, L.P. Common Stock, par value $0.0001 per share | 12.3 | 1,182,624.00 | 02/17/2026 Filed 2026-04-13 | SCHEDULE 13G/AAmendment 3 | Open filing 0001346824-26-000105 Dispute this row |
| Woodline Partners LP Common Stock, par value $0.0001 per share | 6.5 | 625,000.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G | Open filing 0000902664-26-001061 Dispute this row |
| RA Capital Management, L.P. Common Stock, par value $0.0001 per share | 9.9 | 960,237.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 2 | Open filing 0001346824-26-000031 Dispute this row |
| Peter Kolchinsky Common Stock, par value $0.0001 per share | 9.9 | 960,237.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 2 | Open filing 0001346824-26-000031 Dispute this row |
| Rajeev Shah Common Stock, par value $0.0001 per share | 9.9 | 960,237.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 2 | Open filing 0001346824-26-000031 Dispute this row |
| RA Capital Healthcare Fund, L.P. Common Stock, par value $0.0001 per share | 9.9 | 960,237.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 2 | Open filing 0001346824-26-000031 Dispute this row |
| TANG CAPITAL MANAGEMENT, LLC Common Stock, par value $0.0001 per share | 0.1 | 6,158.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 4 | Open filing 0001214659-26-002017 Dispute this row |
| KEVIN TANG Common Stock, par value $0.0001 per share | 0.1 | 6,158.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 4 | Open filing 0001214659-26-002017 Dispute this row |
| TANG CAPITAL PARTNERS, LP Common Stock, par value $0.0001 per share | 0 | 0.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 4 | Open filing 0001214659-26-002017 Dispute this row |
| TANG CAPITAL PARTNERS INTERNATIONAL, LP Common Stock, par value $0.0001 per share | 0.1 | 6,158.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 4 | Open filing 0001214659-26-002017 Dispute this row |
| TANG CAPITAL PARTNERS III, INC Common Stock, par value $0.0001 per share | 0.0 | 0.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 4 | Open filing 0001214659-26-002017 Dispute this row |
| TANG CAPITAL PARTNERS IV, INC Common Stock, par value $0.0001 per share | 0.0 | 0.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 4 | Open filing 0001214659-26-002017 Dispute this row |
| Franklin Resources, Inc. Common Stock, par value $0.0001 per share | 6.5 | 626,571.00 | 12/31/2025 Filed 2026-01-29 | SCHEDULE 13G | Open filing 0000038777-26-000021 Dispute this row |
| Charles B. Johnson Common Stock, par value $0.0001 per share | 0 | 0.00 | 12/31/2025 Filed 2026-01-29 | SCHEDULE 13G | Open filing 0000038777-26-000021 Dispute this row |
| Rupert H. Johnson, Jr. Common Stock, par value $0.0001 per share | 0 | 0.00 | 12/31/2025 Filed 2026-01-29 | SCHEDULE 13G | Open filing 0000038777-26-000021 Dispute this row |
| Franklin Advisers, Inc. Common Stock, par value $0.0001 per share | 6.5 | 626,571.00 | 12/31/2025 Filed 2026-01-29 | SCHEDULE 13G | Open filing 0000038777-26-000021 Dispute this row |
| ORBIMED ADVISORS LLC Common Stock, par value $0.0001 | 9.6 | 14,772,598.00 | 10/08/2025 Filed 2025-10-10 | SCHEDULE 13D/AAmendment 8 | Open filing 0000947871-25-000897 Dispute this row |
| ORBIMED CAPITAL GP VI LLC Common Stock, par value $0.0001 | 2.9 | 4,490,254.00 | 10/08/2025 Filed 2025-10-10 | SCHEDULE 13D/AAmendment 8 | Open filing 0000947871-25-000897 Dispute this row |
| ORBIMED CAPITAL GP V LLC Common Stock, par value $0.0001 | 5.9 | 9,026,359.00 | 10/08/2025 Filed 2025-10-10 | SCHEDULE 13D/AAmendment 8 | Open filing 0000947871-25-000897 Dispute this row |
| OrbiMed Genesis GP LLC Common Stock, par value $0.0001 | 0.8 | 1,255,985.00 | 10/08/2025 Filed 2025-10-10 | SCHEDULE 13D/AAmendment 8 | Open filing 0000947871-25-000897 Dispute this row |
| ORBIMED ADVISORS ISRAEL II LTD Common Stock, par value $0.0001 | 0.4 | 646,657.00 | 10/08/2025 Filed 2025-10-10 | SCHEDULE 13D/AAmendment 8 | Open filing 0000947871-25-000897 Dispute this row |
| ORBIMED ISRAEL GP II, L.P. Common Stock, par value $0.0001 | 0.4 | 646,657.00 | 10/08/2025 Filed 2025-10-10 | SCHEDULE 13D/AAmendment 8 | Open filing 0000947871-25-000897 Dispute this row |
| ORBIMED ISRAEL GP LTD. Common Stock, par value $0.0001 | 0.7 | 1,027,885.00 | 10/08/2025 Filed 2025-10-10 | SCHEDULE 13D/AAmendment 8 | Open filing 0000947871-25-000897 Dispute this row |
| ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIP Common Stock, par value $0.0001 | 0.7 | 1,027,885.00 | 10/08/2025 Filed 2025-10-10 | SCHEDULE 13D/AAmendment 8 | Open filing 0000947871-25-000897 Dispute this row |
Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.
What was read
2,686,506 filings read, dated 2004-06-14 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.
Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.
| Filing year | Filings read |
|---|---|
| 2015 | 103,592 |
| 2016 | 222,642 |
| 2017 | 222,009 |
| 2018 | 223,345 |
| 2019 | 216,482 |
| 2020 | 226,343 |
| 2021 | 249,835 |
| 2022 | 231,682 |
| 2023 | 229,674 |
| 2024 | 234,045 |
| 2025 | 235,520 |
| 2026 | 263,124 |
Filings made before the SEC required XML are listed, not extracted.